
This portfolio primarily directs its capital, dedicating a minimum of 80% of its total assets, towards equity holdings—chiefly common shares—of companies operating within the health sciences and closely related sectors. This comprehensive category includes businesses involved in medical equipment and supplies, healthcare service provision, biotechnology, and pharmaceutical research and manufacturing. The fund maintains a focused investment approach, ensuring that more than a quarter (over 25%) of its assets are committed to these health sciences industries. Additionally, it has the flexibility to include investments in companies based outside of the United States.
Is SHSSX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
No recent news available.